Session 1: Primary Immunodeficiency spectrum: What is new

Chairs:

• Nicholas van Panhuys, Sidra Medicine
• Elif Aydiner, Marmara University, Turkey

• Overview on What’s new in IEI – spectrum & diagnosis
  • Kate Sullivan, Childrens' Hospital of Philadelphia
• Inflammatory bowel disease - gene, mechanisms and treatments
  • Holm Uhlig, Oxford University
• Endosome dysfunction leads to gain-of-function TLR7 and human lupus
  • Fabian Hauck, LMU Munich University Hospital
• An immunodysregulatory syndrome caused by aberrant G-protein signaling
  • Helen Su, NIAID/NIH

Chairs:

• Waleed Al-Herz, Kuwait University
• Aisha Elmarsafy, Cairo University

Career Development Panel Session

Chairs:

• Deena Wafadari, Mohamed Bin Rashid University, UAE
• Rafah Mackeh, Sidra Medicine

Panelists:  

• Medhat Askar, Associate Vice President for Clinical Affairs and Professor of Immunology at Qatar University
• Suleiman Al-Hammadi, Dean of College of Medicine, Mohammed Bin Rashid University, UAE
• Nayef Mazloum, Assistant Dean for Student Research at WCM-Q and Assistant Professor of Microbiology and Immunology at WCM-Q and HBKU
• Samar Al Emadi, Chief of Rheumatology Division and Program Director of Rheumatology Fellowship Program, HMC
• Maryam Al-Nesf, Head of Allergy & Immunology Section and Allergy & Immunology Program Director, HMC
• Ibrahim Janahi, Chair of Medical Education and Division Chief of Pulmonology at Sidra Medicine

Diagnostic challenges in Inborn errors of immunity (Primary Immunodeficiency)

Chairs:

• Suleiman Al-Hammadi, Mohammed Bin Rashid University, UAE
• Michel Massaad, American University of Beirut

• The Ever Changing Genetic Landscape of IEI
  • Jolan Walter, University of South Florida
• Genetics of IEI in the MENA region
  • Hamoud Almousa, King Faisal Specialist Hospital & Research Center
• Importance of functional investigations of Variants of Uncertain Significance (VUS)
  • Amel Hassan, Qatar University
• The subtleties of JAK-STAT biology within the immune system in health and disease
  • Raphaela Goldbach-Mansky, NIAID/NIH
• Rheumatological complications of primary immune dysregulation
  • Raphaela Goldbach-Mansky, NIAID/NIH

Genetic Screening for IEI in the MENA region - Panel discussions

Moderators:

• Bandar Al-Saud, King Faisal Specialist Hospital and Research Centre, KSA
• Bernice Lo, Sidra Medicine

Introductory 15 min talk by Donald Love

Panelists to address the following discussion questions:

• Subcontracting or Developing institutional capacities?
• What strategy for screening: WES or gene panels?
• Bioinformatics capacities to be developed locally or not?
• Integrating AI with bioinformatics

Panelists:

• Anas Alazami, King Faisal Specialist Hospital and Research Centre
• Imen Ben Mustapha, Pasteur Institute of Tunis
• Serdar Ceylaner, Lokman Hekim Üniversitesi
• Wangling Yang, The University of Hong Kong
• Donald Love, Sidra Medicine

Clinical Presentations of Organ-based Immune Dysregulation

Chairs:

• Gehad Elghazali, United Arab Emirates University
•  Sharon Bout-Tabaku, Sidra Medicine

• Clinical features of monogenic immunodysregulation diseases from the Middle East and North Africa registry
  • Hassan Abolhassani, Tehran University of Medical Sciences & Karolinska Institutet
• Allergic and cutaneous presentations in patients with primary immunodysregulation disorders.
  • Ridha Barbouche, Arabian Gulf University
• Malıgnancy as a presenting feature or complication of primary immunodysregulation
  • Nima Rezaei, Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences
• Inflammatory bowel disease: clinical pearls for monogenic vs. polygenic presentation and prognosis
  • Mamoun Elawad, Sidra Medicine
• The frontiers between hypogammaglobulinemia and immune dysregulation among the spectrum of CVID patients
  • Ghassan Dbaibo, American University of Beirut

Abstract Presentations on Organ-based manifestations of immune dysregulation

Chairs:

• Ibtihal Benhsaien, King Hassan II University, Morocco
• Buthaina Al-Adba, Sidra Medicine

Lunch / Jumma prayer

Sponsor workshops:  Biotest (starting 12:00 pm)

• Mohammed Yousuf Karim, Sidra Medicine

Case presentation: Clinical pearls to distinguish IEI from secondary immunodeficiency

Immune Dysregulation Disorders: Emerging Therapeutic Strategies and Modalities

Chairs:

• Mohammed Yousuf Karim, Sidra Medicine
• Deniz Çağdaş Ayvaz, Hacettepe University, Turkey

• Vicki Modell Memorial Lecture
  Updates from the Primary Immune Deficiency Treatment Consortium (PIDTC)
  • Jennifer Puck, University of California – San Francisco
• Leniolisib for APDS/PASLI Disease
  • Mike Lenardo, NIAID/NIH
• Complement Inhibitor Therapy for CHAPLE Disease
  • Ahmet Ozen, Marmara University

Recent Advances in Corrective Therapies for Inborn Errors of Immunity (IEI)

Chairs:

• Aydan Ikincioğulları, Ankara University Medical School, Turkey
•  Raed Alzyoud, Queen Rania Children's Hospital, Jordan

• Gene Therapy for Inborn Errors of Immunity: Current Progress and Prospects
  • Maria Pia Cicalese, San Raffaele Telethon Institute for Gene Therapy
• Lentivirus gene therapy trial for Artemis (DCLRE1C) deficient SCID
  • Jennifer Puck, University of California – San Francisco
• Expanding the Scope of HSCT in the Treatment of IEIs Beyond SCID.
  • Danielle Arnold, Center for Cancer Research/NCI/NIH

Viewpoint topics

Moderators:

• Brahim Belaid, University of Algiers 1, Algeria
• Ihsan Gursel, Bilkent University, Turkey

Curative therapies vs. pharmacotherapy in inborn errors of immunity

Topic 1: LRBA Deficiency/CTLA4 Haploinsufficiency Disorders

• The latest advancements, benefits, and limitations of pharmacotherapy.
  • Safa Baris, Marmara University, School of Medicine
• The effectiveness, challenges, and potential of Hematopoietic Stem Cell Transplantation (HSCT).
  • Figen Doğu, Ankara University, Faculty of Medicine

Topic 2: Chronic Granulomatous Disease

• Insights into pharmacological interventions, their impact, and scope.
  • Jennifer W. Leiding, University of South Florida
• HSCT and emerging gene therapy options: when to consider curative therapies in CGD.
  • Danielle Arnold, National Cancer Institute/NIH